Determination of rivaroxaban in human plasma samples.

@article{Harenberg2012DeterminationOR,
  title={Determination of rivaroxaban in human plasma samples.},
  author={Job Harenberg and Sandra Y. Erdle and Svetlana Marx and Roland Kraemer},
  journal={Seminars in thrombosis and hemostasis},
  year={2012},
  volume={38 2},
  pages={178-84}
}
Rivaroxaban is one of the novel oral direct factor Xa inhibitors, which is effective in preventing thromboembolic complications at fixed doses (i.e., once daily), without the need for dose adjustment according to laboratory monitoring. Nearly 60% of rivaroxaban is cleared from circulation by glomerular filtration, 30% of which is excreted as active drug… CONTINUE READING